NSE · REMUS
Remus Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹860 Cr with net profit ₹37 Cr — a 4.3% net margin, versus 4.65% the period before.
Shareholding
As of 2026-09-30
- Promoter70.95%
- Public23.52%
- FII5.1%
- DII0.43%
2,092 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.79× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #1 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,20,603 Cr | 33.29 | 5.03 | 13.74% | 20.29% |
| Laurus Labs Limited | ₹1,17,788 Cr | 107.71 | 22.22 | 16.77% | 15.04% |
| Zydus Lifesciences Ltd. | ₹1,17,546 Cr | 24.07 | 4.34 | 18.59% | 16.09% |
| Dr Reddys Laboratories Ltd. | ₹1,10,537 Cr | 39.48 | 2.85 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,09,757 Cr | 35.34 | 3.1 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,02,708 Cr | 44.02 | 5.84 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹94,420 Cr | 24.97 | 2.49 | 9.25% | 10.7% |
| Lupin Limited | ₹89,794 Cr | 15.08 | 4 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹65,025 Cr | 20.83 | 6.19 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹60,374 Cr | 26.5 | 4.37 | 16.66% | 14.31% |
| Remus Pharmaceuticals Limited(this company) | — | 40.78 | 3.09 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashRemus Pharmaceuticals Limited (REMUS) has a market capitalization of Rs 2252 Cr. The company reported revenue of Rs 625.34 Cr, representing a revenue growth of 191.3%. Its debt-to-equity ratio stands at 0.09.
Positives
- +Revenue growth was 191.3% in the latest period.
- +Debt-to-equity ratio is low at 0.09, indicating sound financial leverage.
- +Promoter holding is high at 70.95% as of March 31, 2026.
- +The Return on Capital Employed (ROCE) is 21.6%.
Negatives
- −Promoter shareholding has decreased from 70.85% in March 2025 to 70.95% in March 2026.
- −No quarterly results have been disclosed.
Financial performance
Remus Pharmaceuticals Limited reported revenue of Rs 625.34 Cr in the latest financial period. This represents a substantial revenue growth of 191.3%. The Earnings Per Share (EPS) for the latest period is Rs 20.97.
Balance sheet
The company maintains a low debt-to-equity ratio of 0.09, suggesting limited reliance on borrowed capital. The book value per share is Rs 276.4.
Profitability & Returns
Remus Pharmaceuticals Limited has a Return on Capital Employed (ROCE) of 21.6%. The company's P/E ratio is 34.28 based on its EPS of Rs 20.97.
Ownership & Pledges
The public shareholding stands at 22.93%. There are no promoter pledged shares reported.
Data as of — price: 2026-10-28 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Remus Pharmaceuticals Limitedshare price & fundamentals